CGRP阻害剤市場- 世界の産業規模、シェア、動向、機会、予測、治療別、投与経路別、エンドユーザー別、地域別、競合別、2020～2030年

CGRP阻害剤の世界市場規模は2024年に32億9,000万米ドルで、予測期間中のCAGRは9.72%で2030年には48億7,000万米ドルに達すると予測されています。

CGRP阻害剤の世界市場は、製薬・ヘルスケア業界の中でもダイナミックで急速に発展している分野として浮上しています。CGRP（カルシトニン遺伝子関連ペプチド）阻害剤は、片頭痛や群発頭痛などの衰弱状態に対処し、緩和するために設計された新しい薬剤クラス別です。この市場は、世界の片頭痛の有病率の増加と、既存の治療オプションの有効性が限られていることから、大幅な成長と技術革新を目の当たりにしています。2024年3月に発表された世界保健機関（WHO）の論文によると、2021年には世界人口の推定40％、約31億人に相当する人々が片頭痛やその他の頭痛障害を経験しています。

世界のCGRP阻害剤市場拡大の主な促進要因の1つは、偏頭痛の発生率の上昇であり、世界中の何百万人もの人々に影響を及ぼしています。片頭痛は耐え難い痛みをもたらすだけでなく、欠勤や生産性の低下により経済的負担も大きくなります。その結果、製薬会社はCGRP阻害剤の研究開発に多大な投資を行っており、片頭痛発作の頻度と重症度の軽減に顕著な効果を示しています。さらに、さまざまなCGRP阻害剤がFDAに承認され、その安全性と有効性が示されたことも、市場の成長を後押ししています。これらの承認により、ヘルスケアプロバイダーや患者の間でCGRP阻害剤が広く採用される道が開かれました。その結果、同市場では複数のブランド薬やジェネリック医薬品が発売され、患者に幅広い選択肢を提供し、市場拡大に貢献しています。さらに、世界のCGRP阻害剤市場は製薬大手間の激しい競合が特徴であり、各社は患者の予後を改善するために革新的な製剤や投与方法の開発に絶えず取り組んでいます。さらに、バイオテクノロジーと神経科学の進歩により、片頭痛の根本的なメカニズムの理解が促進され、より的を絞った効果的なCGRP阻害剤の開発につながっています。

主な市場促進要因

片頭痛および群発頭痛の有病率の上昇

主な市場課題

高額な治療費とアクセシビリティの問題

主要市場動向

バイオシミラーとジェネリック医薬品の台頭

• CGRP阻害剤のような効果的な治療を必要とする患者層が、この地域に多数存在しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のCGRP阻害剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別（予防、急性）
  • 投与経路別（経口、経鼻、静脈内）
  • エンドユーザー別（病院、薬局、専門クリニック）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のCGRP阻害剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のCGRP阻害剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のCGRP阻害剤市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のCGRP阻害剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのCGRP阻害剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Eli Lilly and Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Amgen Inc
• Novartis AG
• Allergan
• Biohaven Pharmaceutical Holding Company Ltd.
• Sun Pharmaceutical Industries Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global CGRP Inhibitor Market was valued at USD 3.29 Billion in 2024 and is expected to reach USD 4.87 Billion by 2030 with a CAGR of 9.72% during the forecast period. The Global CGRP Inhibitor Market has emerged as a dynamic and rapidly evolving sector within the pharmaceutical and healthcare industry. CGRP (Calcitonin Gene-Related Peptide) inhibitors represent a novel class of drugs designed to address and alleviate debilitating conditions such as migraines and cluster headaches. This market has witnessed substantial growth and innovation due to the increasing prevalence of migraine disorders worldwide and the limited effectiveness of existing treatment options. As per the World Health Organization (WHO) article published in March 2024, an estimated 40% of the global population, equivalent to approximately 3.1 billion individuals, experienced migraine and other headache disorders in 2021.

One of the key drivers behind the expansion of the Global CGRP Inhibitor Market is the rising incidence of migraines, affecting millions of people across the globe. Migraines not only result in excruciating pain but also lead to substantial economic burdens due to missed workdays and reduced productivity. As a result, pharmaceutical companies have invested heavily in research and development efforts to create CGRP inhibitors, which have shown remarkable efficacy in reducing the frequency and severity of migraine attacks. Furthermore, the market's growth is bolstered by the FDA approvals of various CGRP inhibitors, signaling their safety and efficacy. These approvals have paved the way for a wider adoption of CGRP inhibitors among healthcare providers and patients. As a result, the market has witnessed the launch of several branded and generic CGRP inhibitor drugs, offering a broader range of choices to patients and contributing to market expansion. Moreover, the Global CGRP Inhibitor Market is characterized by intense competition among pharmaceutical giants, with companies constantly striving to develop innovative formulations and delivery methods to improve patient outcomes. Additionally, advancements in biotechnology and neuroscience have facilitated a better understanding of the underlying mechanisms of migraine, leading to the development of more targeted and effective CGRP inhibitors.

Key Market Drivers

Rising Prevalence of Migraines and Cluster Headaches

The Global CGRP (Calcitonin Gene-Related Peptide) Inhibitor Market has witnessed a significant boost in recent years, largely attributable to the rising prevalence of migraines and cluster headaches worldwide. Migraines, characterized by intense and debilitating headaches often accompanied by nausea, vomiting, and sensitivity to light and sound, affect an ever-increasing number of individuals globally. Similarly, cluster headaches, though less common, are excruciatingly painful and tend to occur in clusters or cycles, affecting individuals' quality of life .In June 2023, during Migraine and Headache Awareness Month, the foundation introduced the "GET HEADUCATED" campaign to emphasize the importance of educating individuals and communities about the disorder. This initiative aims to mobilize the community in addressing stigma associated with the condition while fostering greater awareness, ultimately driving the adoption of treatment options.

The sheer magnitude of these disorders' impact on individuals, both in terms of physical suffering and the socioeconomic burden they impose, has prompted a growing demand for more effective treatment options. Traditional remedies, including over-the-counter pain relievers and preventive medications, often provide limited relief and are associated with various side effects, leaving patients and healthcare providers seeking alternative solutions. CGRP inhibitors have emerged as a ray of hope in this landscape, as they address the root causes of migraines and cluster headaches, offering more effective and well-tolerated treatment options.

The rising prevalence of migraines and cluster headaches has not only increased the patient pool but has also garnered attention from the pharmaceutical industry. Recognizing the immense unmet medical need and the potential market opportunity, pharmaceutical companies have ramped up their research and development efforts to create innovative CGRP inhibitor formulations. This surge in investment has resulted in the development of a diverse range of CGRP inhibitors, including monoclonal antibodies and small molecules, each designed to cater to the specific needs of patients.

Moreover, the heightened awareness of migraine and cluster headache disorders, fueled by patient advocacy groups and healthcare campaigns, has further accelerated diagnosis and treatment initiation. Patients are more informed about their condition, and healthcare providers are increasingly recognizing the potential benefits of CGRP inhibitors in providing effective and sustainable relief.

Key Market Challenges

High Treatment Costs and Accessibility Issues

CGRP inhibitors are at the forefront of migraine and cluster headache treatments due to their efficacy and novel mechanisms of action. However, their development involves extensive research, clinical trials, and biotechnological processes, making them expensive to produce. As a result, the price tag attached to CGRP inhibitors is often exceptionally high, putting them out of reach for many patients. Even when patients recognize the potential benefits of CGRP inhibitors, many face insurmountable challenges when seeking insurance coverage or reimbursement for these treatments. Insurance companies and healthcare payers may be hesitant to cover the cost of CGRP inhibitors due to their high price, requiring substantial evidence of cost-effectiveness and long-term safety. This reluctance can limit patient access, leaving them to shoulder the financial burden themselves.

The accessibility issues are further exacerbated in developing regions where healthcare infrastructure may be lacking, and patients may not have the financial means to afford these costly treatments. This disparity in access to CGRP inhibitors underscores a global healthcare divide, leaving many individuals without access to cutting-edge migraine and cluster headache therapies. High treatment costs can not only deter patients from starting CGRP inhibitor therapies but also lead to non-adherence, as some patients may ration or skip doses to make their medication last longer. This compromises the effectiveness of the treatment and may contribute to suboptimal outcomes.

Key Market Trends

Emerging Biosimilars and Generics

Emerging biosimilars and generics are playing a pivotal role in boosting the Global CGRP (Calcitonin Gene-Related Peptide) Inhibitor Market. These cost-effective alternatives to branded CGRP inhibitors are reshaping the treatment landscape for migraine and cluster headache sufferers.

Biosimilars, which are biologic drugs similar to the original CGRP inhibitors, offer comparable efficacy and safety profiles at a reduced cost. They are gaining traction in the market as patents for some branded CGRP inhibitors expire. Biosimilars present a win-win situation, allowing patients to access CGRP inhibitor therapies at more affordable prices while increasing market competitiveness. Generics, on the other hand, are non-branded versions of the original CGRP inhibitors. As patents expire, generic versions become available, offering a more budget-friendly option for patients. This trend is particularly significant in healthcare systems where cost considerations heavily influence treatment decisions.

The emergence of biosimilars and generics addresses the issue of treatment affordability and accessibility, breaking down barriers that once hindered patient access to CGRP inhibitors. As competition increases, the prices of these medications are likely to decrease, making CGRP inhibitor therapies available to a broader patient population, including those with limited insurance coverage or residing in regions with constrained healthcare resources. Moreover, the presence of biosimilars and generics encourages pharmaceutical companies to stay competitive by continuously improving their products and services. This competitive environment can drive innovation and lead to the development of more efficient and cost-effective CGRP inhibitor therapies.

• f individuals in the region, creating a substantial patient pool in need of effective treatments like CGRP inhibitors.

Key Market Players

• Eli Lilly and Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• AbbVie Inc.
• Amgen Inc
• Novartis AG
• Allergan
• Biohaven Pharmaceutical Holding Company Ltd.
• Sun Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global CGRP Inhibitor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CGRP Inhibitor Market, By Treatment:

• Preventive
• Acute

CGRP Inhibitor Market, By Route of Administration:

• Oral
• Nasal
• Intravenous

CGRP Inhibitor Market, By End-User:

• Hospitals
• Pharmacies
• Specialty Clinics

CGRP Inhibitor Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CGRP Inhibitor Market.

Available Customizations:

Global CGRP Inhibitor Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CGRP Inhibitor Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Preventive, Acute)
  • 5.2.2. By Route of Administration (Oral, Nasal, Intravenous)
  • 5.2.3. By End-User (Hospitals, Pharmacies, Specialty Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America CGRP Inhibitor Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Route of Administration
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States CGRP Inhibitor Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada CGRP Inhibitor Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico CGRP Inhibitor Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By End-User

7. Europe CGRP Inhibitor Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Route of Administration
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany CGRP Inhibitor Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By End-User
  • 7.3.2. United Kingdom CGRP Inhibitor Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By End-User
  • 7.3.3. Italy CGRP Inhibitor Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By End-User
  • 7.3.4. France CGRP Inhibitor Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain CGRP Inhibitor Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By End-User

8. Asia-Pacific CGRP Inhibitor Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Route of Administration
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China CGRP Inhibitor Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End-User
  • 8.3.2. India CGRP Inhibitor Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan CGRP Inhibitor Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea CGRP Inhibitor Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia CGRP Inhibitor Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By End-User

9. South America CGRP Inhibitor Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Route of Administration
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil CGRP Inhibitor Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina CGRP Inhibitor Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia CGRP Inhibitor Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End-User

10. Middle East and Africa CGRP Inhibitor Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Route of Administration
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa CGRP Inhibitor Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia CGRP Inhibitor Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE CGRP Inhibitor Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Teva Pharmaceutical Industries Ltd
• 14.4. Amgen Inc
• 14.5. Novartis AG
• 14.6. Allergan
• 14.7. Biohaven Pharmaceutical Holding Company Ltd.
• 14.8. Sun Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer